Sassi Karina Lúcia Moreira, Martins Laís Bhering, de Miranda Aline Silva, Teixeira Antonio Lucio
Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Department of Morphology, Institute of Biological Sciences, The Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.
Protein Pept Lett. 2020;27(6):512-519. doi: 10.2174/0929866527666200129160136.
Migraine is a common neurologic condition marked by recurrent episodes of headache. Its pathophysiology is highly complex involving neuronal, inflammatory and vascular mechanisms. The Renin-Angiotensin System (RAS) can modulate all these mechanism, being a potential pharmacological target for migraine treatment. We carried out a systematic review of the studies evaluating the involvement of RAS in patients with migraine. There is evidence from genetic studies exploring the relation between migraine and RAS-related genes and from clinical trials evaluating the efficacy of Angiotensin II Type 1 (AT1) receptor antagonists and angiotensin converting enzyme inhibitors in migraine prophylaxis. RAS seems to play a role in the pathophysiology of migraine, but more direct evidence is still missing.
偏头痛是一种常见的神经系统疾病,其特征为反复出现头痛发作。其病理生理学高度复杂,涉及神经元、炎症和血管机制。肾素-血管紧张素系统(RAS)可以调节所有这些机制,是偏头痛治疗的一个潜在药理学靶点。我们对评估RAS在偏头痛患者中的作用的研究进行了系统综述。有来自探索偏头痛与RAS相关基因之间关系的遗传学研究以及评估1型血管紧张素II(AT1)受体拮抗剂和血管紧张素转换酶抑制剂在偏头痛预防中的疗效的临床试验的证据。RAS似乎在偏头痛的病理生理学中起作用,但仍缺乏更直接的证据。